(Boursier.com) — Cellectis announces that during its meeting of June 27, the general meeting of Cellectis appointed Dr. Cécile Chartier, PhD, as director of the board of directors of the company, with immediate effect. “We are very pleased to welcome Dr. Chartier to the Cellectis Board of Directors as a director. His extensive experience in the development of next-generation cell and gene therapies, combined with his in-depth knowledge of the industry American biotechnology company, will be a considerable asset for the company,” said Dr. André Choulika, PhD., Chief Executive Officer of Cellectis. “We look forward to his input and insights into the development of our product candidates.”
Cécile Chartier, Ph.D., is currently Chief Scientific Officer of NextVivo, Inc. Prior to joining NextVivo, Dr. Chartier served as Vice President of Research at Iovance Biotherapeutics, Inc., where she led the development of therapeutics next-generation tumor-infiltrating lymphocytes (TILs), from research to early clinical trials. Previously, Cécile Chartier worked for 12 years at OncoMed Pharmaceuticals, where she held the position of Senior Director of Target Validation and led several teams of therapeutic projects on antibodies, from research to development to the filing of an application. clinical trial authorization in the United States (IND). She also worked at Shering (US Berlin) and Transgene (France), where she focused on gene therapy.
During the session, the Cellectis share gained 0.79%, reaching 2.054 euros.
©2023 Boursier.com